Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5

E. K. Mai, U. Bertsch,J. Duerig,C. Kunz,M. Haenel,I. W. Blau,M. Munder,A. Jauch, B. Schurich,T. Hielscher,M. Merz, B. Huegle-Doerr,A. Seckinger, D. Hose, J. Hillengass, M. S. Raab, K. Neben,H-W Lindemann,M. Zeis, C. Gerecke, I. G. H. Schmidt-Wolf, K. Weisel, C. Scheid,H. Salwender, H. Goldschmidt

ONCOLOGY RESEARCH AND TREATMENT(2014)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要